𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Selegiline and levodopa in early or moderately advanced Parkinson's disease: a double-blind controlled short- and long-term study

✍ Scribed by B. Sivertsen; E. Dupont; B. Mikkelsen; P. Mogensen; C. Rasmussen; F. Boesen; E. Heinonen

Book ID
114782835
Publisher
John Wiley and Sons
Year
1989
Tongue
English
Weight
373 KB
Volume
80
Category
Article
ISSN
0001-6314

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Levodopa improves physical fatigue in Pa
Levodopa improves physical fatigue in Parkinson's disease: A double-blind, placebo-controlled, crossover study
✍ Jau-Shin Lou; Greg Kearns; Theodore Benice; Barry Oken; Gary Sexton; John Nutt πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 110 KB

## Abstract We quantitatively investigated the effect of carbidopa/levodopa (25/100) on physical fatigue during finger tapping and force generation in a double‐blind, placebo‐controlled crossover study. Parkinson's disease (PD) subjects were randomly assigned to carbidopa/levodopa or placebo for Vi

Acute effects of immediate and controlle
Acute effects of immediate and controlled-release levodopa on mood in Parkinson's disease: A double-blind study
✍ Jaime Kulisevsky; Berta Pascual-Sedano; Manel Barbanoj; Alexandre Gironell; Javi πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 141 KB πŸ‘ 1 views

Mood fluctuations related to levodopa (LD) dosing are well-known psychiatric complications of Parkinson's disease (PD). No formal studies explored how affective response to LD relates to the type of motor response to oral LD (stable or wearing-off) and to different pharmacokinetic profiles of oral L

Rotigotine transdermal patch in early Pa
Rotigotine transdermal patch in early Parkinson's disease: A randomized, double-blind, controlled study versus placebo and ropinirole
✍ Nir Giladi; Babak Boroojerdi; Amos D. Korczyn; David J. Burn; Carl E. Clarke; An πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 167 KB

## Abstract Rotigotine is a new, non‐ergot dopamine agonist formulated in a transdermal delivery system. The present study was to investigate the efficacy and safety of the rotigotine transdermal patch in the treatment of early Parkinson's disease. Patients (n = 561) were randomized to rotigotine,